GRFS (Grifols) Valuation Rank


GRFS Grifols SA GRFS
84 GF Score
Price $7.36
GF Value $9.81
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Grifols Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Grifols Valuation Rank Related Terms

GRFS
84GF Score
Grifols SA GRFS
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Grifols (GRFS) Overvalued in 2026?

Based on GuruFocus' analysis, Grifols stock appears to be undervalued. The current stock price of $7.36 is trading 25% below its estimated GF Value™ of $9.81. GuruFocus considers Grifols to be Modestly Undervalued.

Key valuation signals for GRFS:

  • Valuation Rank:
  • GF Value™: $9.81 vs. price of $7.36 (25% below fair value)
  • GF Score™: 84/100 with 6 warning signs

No single metric tells the full story. See the GRFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Grifols Business Description

Address Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
84GF Score

Get the complete analysis for GRFS

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.36
Price
$9.81
GF Value